Key Points Bristol Myers Squibb maintains a deep portfolio of oncology and immunology treatments while generating high levels of free cash flow. Eli Lilly and is seeing explosive revenue growth driven by its market-leading metabolic and injectable drug platforms. Should you prioritize value and dividends or high-octane pharmaceutical growth for your 2026 portfolio? 10 stocks we like better than Bristol Myers Squibb › Bristol Myers Squibb (NYSE:BMY) and Eli Lilly & Co (NYSE:LLY) represent two different paths in the healthcare market. Choosing between a deep-value dividend payer and a high-growth pharmaceutical juggernaut is the ultimate dilemma for investors today.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.